{"id":371,"date":"2025-03-08T23:38:17","date_gmt":"2025-03-08T23:38:17","guid":{"rendered":"https:\/\/rheumanext.pl\/?page_id=371"},"modified":"2026-03-14T20:08:14","modified_gmt":"2026-03-14T20:08:14","slug":"eozynofilowa-ziarniniakowatosc-z-zapaleniem-naczyn-zespol-churga-i-strauss-egpa-acr-eular-2022","status":"publish","type":"page","link":"https:\/\/rheumanext.pl\/en\/kalkulatory\/kryteria\/eozynofilowa-ziarniniakowatosc-z-zapaleniem-naczyn-zespol-churga-i-strauss-egpa-acr-eular-2022\/","title":{"rendered":"Eozynofilowa ziarniniakowato\u015b\u0107 z zapaleniem naczy\u0144 (zesp\u00f3\u0142 Churga i Strauss, EGPA) &#8211; ACR\/EULAR 2022"},"content":{"rendered":"\n<section id=\"rx-egpa-acr-eular-2022-calculator\" style=\"max-width:960px;margin:0 auto;font:16px\/1.55 Inter,ui-sans-serif,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',sans-serif;color:#0f172a;\">\n  <div style=\"background:linear-gradient(180deg,#ffffff 0%,#fbfdff 100%);border:1px solid #e2e8f0;border-radius:24px;box-shadow:0 12px 30px rgba(15,23,42,.06);overflow:hidden;\">\n    <div style=\"padding:28px 28px 20px;border-bottom:1px solid #e2e8f0;background:radial-gradient(circle at top right, rgba(15,118,110,.08), transparent 32%), linear-gradient(180deg,#ffffff 0%,#f8fafc 100%);\">\n      <div style=\"display:inline-block;padding:6px 12px;border-radius:999px;background:rgba(15,118,110,.10);color:#0f766e;font-size:12px;font-weight:700;letter-spacing:.02em;text-transform:uppercase;margin-bottom:14px;\">Kalkulator klasyfikacyjny<\/div>\n      <h2 style=\"margin:0 0 10px;font-size:clamp(24px,3vw,32px);line-height:1.15;letter-spacing:-.02em;\">Eozynofilowa ziarniniakowato\u015b\u0107 z zapaleniem naczy\u0144 (EGPA) \u2014 ACR\/EULAR 2022<\/h2>\n      <p style=\"margin:0;color:#475569;max-width:76ch;\">Kryteria stosuje si\u0119 po rozpoznaniu zapalenia naczy\u0144 ma\u0142ych lub \u015brednich naczy\u0144 oraz po wykluczeniu rozpozna\u0144 na\u015bladuj\u0105cych vasculitis. Nast\u0119pnie sumuje si\u0119 punkty; wynik \u22656 pkt klasyfikuje EGPA.<\/p>\n    <\/div>\n\n    <div style=\"padding:28px;display:grid;gap:20px;\">\n      <div style=\"background:#fff;border:1px solid #e2e8f0;border-radius:20px;padding:20px;\">\n        <h3 style=\"margin:0 0 6px;font-size:18px;\">1. Warunek wst\u0119pny<\/h3>\n        <p style=\"margin:0 0 16px;color:#475569;font-size:14px;\">Czy rozpoznano zapalenie naczy\u0144 ma\u0142ych lub \u015brednich naczy\u0144 oraz wykluczono rozpoznania na\u015bladuj\u0105ce vasculitis?<\/p>\n\n        <label style=\"display:flex;align-items:flex-start;gap:10px;padding:12px 14px;border:1px solid #e2e8f0;border-radius:16px;margin-bottom:10px;background:#fff;cursor:pointer;\">\n          <input type=\"radio\" name=\"rx-egpa-entry\" id=\"rx-egpa-entry-no\" value=\"no\" checked style=\"margin-top:3px;accent-color:#0f766e;\">\n          <span><strong>Nie<\/strong><\/span>\n        <\/label>\n\n        <label style=\"display:flex;align-items:flex-start;gap:10px;padding:12px 14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n          <input type=\"radio\" name=\"rx-egpa-entry\" id=\"rx-egpa-entry-yes\" value=\"yes\" style=\"margin-top:3px;accent-color:#0f766e;\">\n          <span><strong>Tak<\/strong><\/span>\n        <\/label>\n      <\/div>\n\n      <div style=\"background:#fff;border:1px solid #e2e8f0;border-radius:20px;padding:20px;\">\n        <h3 style=\"margin:0 0 6px;font-size:18px;\">2. Kryteria punktowane<\/h3>\n        <p style=\"margin:0 0 16px;color:#475569;font-size:14px;\">Zaznacz wszystkie obecne pozycje. Punkty dodatnie i ujemne sumuj\u0105 si\u0119.<\/p>\n\n        <div style=\"display:grid;gap:20px;\">\n          <div>\n            <p style=\"margin:0 0 12px;font-weight:800;color:#0f172a;\">A. Kliniczne<\/p>\n            <div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(240px,1fr));gap:12px;\">\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-airway\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Obturacyjna choroba dr\u00f3g oddechowych<\/strong><br><span style=\"color:#475569;font-size:13px;\">najcz\u0119\u015bciej astma<\/span><br><span style=\"color:#166534;font-size:13px;\">+3 pkt<\/span><\/span>\n              <\/label>\n\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-polyps\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Polipy nosa<\/strong><br><span style=\"color:#475569;font-size:13px;\">Nasal polyps<\/span><br><span style=\"color:#166534;font-size:13px;\">+3 pkt<\/span><\/span>\n              <\/label>\n\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-neuropathy\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Mononeuritis multiplex lub neuropatia ruchowa<\/strong><br><span style=\"color:#475569;font-size:13px;\">nie z powodu radikulopatii<\/span><br><span style=\"color:#166534;font-size:13px;\">+1 pkt<\/span><\/span>\n              <\/label>\n            <\/div>\n          <\/div>\n\n          <div>\n            <p style=\"margin:0 0 12px;font-weight:800;color:#0f172a;\">B. Serologia \/ morfologia<\/p>\n            <div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(240px,1fr));gap:12px;\">\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-eos\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Maksymalna liczba eozynofili \u22651 \u00d7 10\u2079\/l<\/strong><br><span style=\"color:#475569;font-size:13px;\">Maximum eosinophil count \u22651 \u00d7 10\u2079\/L<\/span><br><span style=\"color:#166534;font-size:13px;\">+5 pkt<\/span><\/span>\n              <\/label>\n\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-pr3\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>c-ANCA lub anty-PR3 dodatnie<\/strong><br><span style=\"color:#475569;font-size:13px;\">Cytoplasmic ANCA or anti-PR3 positivity<\/span><br><span style=\"color:#92400e;font-size:13px;\">\u22123 pkt<\/span><\/span>\n              <\/label>\n\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-hematuria\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Krwiomocz<\/strong><br><span style=\"color:#475569;font-size:13px;\">Haematuria<\/span><br><span style=\"color:#92400e;font-size:13px;\">\u22121 pkt<\/span><\/span>\n              <\/label>\n            <\/div>\n          <\/div>\n\n          <div>\n            <p style=\"margin:0 0 12px;font-weight:800;color:#0f172a;\">C. Histopatologia<\/p>\n            <div style=\"display:grid;grid-template-columns:repeat(auto-fit,minmax(240px,1fr));gap:12px;\">\n              <label style=\"display:flex;align-items:flex-start;gap:10px;padding:14px;border:1px solid #e2e8f0;border-radius:16px;background:#fff;cursor:pointer;\">\n                <input type=\"checkbox\" id=\"rx-egpa-biopsy\" style=\"margin-top:3px;accent-color:#0f766e;\">\n                <span><strong>Pozanaczyniowe zapalenie z przewag\u0105 eozynofil\u00f3w<\/strong><br><span style=\"color:#475569;font-size:13px;\">Extravascular eosinophilic-predominant inflammation on biopsy<\/span><br><span style=\"color:#166534;font-size:13px;\">+2 pkt<\/span><\/span>\n              <\/label>\n            <\/div>\n          <\/div>\n        <\/div>\n      <\/div>\n\n      <div style=\"display:flex;flex-wrap:wrap;gap:12px;margin-top:2px;\">\n        <button\n          type=\"button\"\n          id=\"rx-egpa-calc-btn\"\n          style=\"appearance:none;border:0;border-radius:16px;padding:14px 18px;background:linear-gradient(180deg,#0f766e 0%,#115e59 100%);color:#fff;font:inherit;font-weight:700;cursor:pointer;box-shadow:0 12px 24px rgba(15,118,110,.22);display:inline-flex;align-items:center;justify-content:center;min-width:180px;\"\n        >Oblicz wynik<\/button>\n\n        <button\n          type=\"button\"\n          id=\"rx-egpa-clear-btn\"\n          style=\"appearance:none;border:1px solid #cbd5e1;border-radius:16px;padding:14px 18px;background:#fff;color:#0f172a;font:inherit;font-weight:700;cursor:pointer;display:inline-flex;align-items:center;justify-content:center;\"\n        >Wyczy\u015b\u0107<\/button>\n      <\/div>\n\n      <div id=\"rx-egpa-result\" style=\"display:block;border-radius:20px;padding:20px;border:1px solid #e2e8f0;background:#f8fafc;\">\n        <p id=\"rx-egpa-result-title\" style=\"margin:0 0 8px;font-size:18px;line-height:1.3;font-weight:800;color:#0f172a;\">Wynik pojawi si\u0119 tutaj<\/p>\n        <p id=\"rx-egpa-result-text\" style=\"margin:0 0 8px;\">Zaznacz odpowiedzi, a nast\u0119pnie kliknij \u201eOblicz wynik\u201d.<\/p>\n        <p id=\"rx-egpa-result-note\" style=\"margin:0;color:#475569;font-size:14px;\">Regu\u0142a: po spe\u0142nieniu warunku wst\u0119pnego zsumuj punkty. Wynik \u22656 pkt klasyfikuje EGPA wed\u0142ug ACR\/EULAR 2022.<\/p>\n      <\/div>\n\n      <div style=\"border:1px solid #e2e8f0;background:linear-gradient(180deg,#ffffff 0%,#f8fafc 100%);border-radius:18px;padding:16px 18px;color:#475569;font-size:14px;\">\n        <strong style=\"color:#0f172a;\">Uwaga:<\/strong> to narz\u0119dzie wspiera klasyfikacj\u0119 EGPA i nie zast\u0119puje pe\u0142nej oceny klinicznej. Kryteria klasyfikacyjne nie s\u0105 samodzielnym narz\u0119dziem diagnostycznym. Edukacyjnie. Nie zast\u0119puje konsultacji lekarskiej.\n      <\/div>\n    <\/div>\n  <\/div>\n<\/section>\n\n<script>\n(function () {\n  var calcBtn = document.getElementById('rx-egpa-calc-btn');\n  var clearBtn = document.getElementById('rx-egpa-clear-btn');\n\n  if (!calcBtn || !clearBtn) return;\n\n  calcBtn.addEventListener('click', function () {\n    var entryMet = document.getElementById('rx-egpa-entry-yes').checked;\n\n    var items = [\n      ['rx-egpa-eos', 5, 'maksymalna liczba eozynofili \u22651 \u00d7 10\u2079\/l (+5)'],\n      ['rx-egpa-airway', 3, 'obturacyjna choroba dr\u00f3g oddechowych (+3)'],\n      ['rx-egpa-polyps', 3, 'polipy nosa (+3)'],\n      ['rx-egpa-pr3', -3, 'c-ANCA lub anty-PR3 dodatnie (\u22123)'],\n      ['rx-egpa-biopsy', 2, 'pozanaczyniowe zapalenie z przewag\u0105 eozynofil\u00f3w w biopsji (+2)'],\n      ['rx-egpa-neuropathy', 1, 'mononeuritis multiplex \/ neuropatia ruchowa (+1)'],\n      ['rx-egpa-hematuria', -1, 'krwiomocz (\u22121)']\n    ];\n\n    var total = 0;\n    var positiveList = [];\n    var negativeList = [];\n\n    items.forEach(function (item) {\n      var el = document.getElementById(item[0]);\n      if (el && el.checked) {\n        total += item[1];\n        if (item[1] >= 0) {\n          positiveList.push(item[2]);\n        } else {\n          negativeList.push(item[2]);\n        }\n      }\n    });\n\n    var result = document.getElementById('rx-egpa-result');\n    var title = document.getElementById('rx-egpa-result-title');\n    var text = document.getElementById('rx-egpa-result-text');\n    var note = document.getElementById('rx-egpa-result-note');\n\n    result.style.display = 'block';\n\n    if (!entryMet) {\n      result.style.background = '#fef2f2';\n      result.style.border = '1px solid #fecaca';\n      title.style.color = '#991b1b';\n      title.innerHTML = 'Warunek wst\u0119pny niespe\u0142niony';\n      text.innerHTML = 'Kryteri\u00f3w EGPA ACR\/EULAR 2022 nie stosuje si\u0119 bez rozpoznania zapalenia naczy\u0144 ma\u0142ych lub \u015brednich naczy\u0144 oraz po wykluczeniu rozpozna\u0144 na\u015bladuj\u0105cych vasculitis.';\n      note.innerHTML = 'Najpierw musi by\u0107 spe\u0142niony warunek wej\u015bciowy, dopiero potem interpretuje si\u0119 wynik punktowy.';\n      return;\n    }\n\n    if (total >= 6) {\n      result.style.background = '#f0fdf4';\n      result.style.border = '1px solid #bbf7d0';\n      title.style.color = '#166534';\n      title.innerHTML = 'Kryteria spe\u0142nione';\n      text.innerHTML = 'Spe\u0142niono kryteria klasyfikacyjne ACR\/EULAR 2022 dla eozynofilowej ziarniniakowato\u015bci z zapaleniem naczy\u0144 (EGPA).';\n      note.innerHTML = 'Suma punkt\u00f3w: ' + total + '.';\n      if (positiveList.length) {\n        note.innerHTML += ' Kryteria dodatnie: ' + positiveList.join('; ') + '.';\n      }\n      if (negativeList.length) {\n        note.innerHTML += ' Kryteria ujemne: ' + negativeList.join('; ') + '.';\n      }\n    } else {\n      result.style.background = '#fffbeb';\n      result.style.border = '1px solid #fde68a';\n      title.style.color = '#92400e';\n      title.innerHTML = 'Kryteria niespe\u0142nione';\n      text.innerHTML = 'Nie osi\u0105gni\u0119to progu klasyfikacyjnego dla EGPA wed\u0142ug ACR\/EULAR 2022.';\n      note.innerHTML = 'Suma punkt\u00f3w: ' + total + '. Do klasyfikacji potrzeba co najmniej 6 pkt.';\n      if (positiveList.length) {\n        note.innerHTML += ' Kryteria dodatnie: ' + positiveList.join('; ') + '.';\n      }\n      if (negativeList.length) {\n        note.innerHTML += ' Kryteria ujemne: ' + negativeList.join('; ') + '.';\n      }\n    }\n  });\n\n  clearBtn.addEventListener('click', function () {\n    document.getElementById('rx-egpa-entry-no').checked = true;\n\n    [\n      'rx-egpa-eos',\n      'rx-egpa-airway',\n      'rx-egpa-polyps',\n      'rx-egpa-pr3',\n      'rx-egpa-biopsy',\n      'rx-egpa-neuropathy',\n      'rx-egpa-hematuria'\n    ].forEach(function (id) {\n      document.getElementById(id).checked = false;\n    });\n\n    document.getElementById('rx-egpa-result').style.display = 'block';\n    document.getElementById('rx-egpa-result').style.background = '#f8fafc';\n    document.getElementById('rx-egpa-result').style.border = '1px solid #e2e8f0';\n    document.getElementById('rx-egpa-result-title').style.color = '#0f172a';\n    document.getElementById('rx-egpa-result-title').innerHTML = 'Wynik pojawi si\u0119 tutaj';\n    document.getElementById('rx-egpa-result-text').innerHTML = 'Zaznacz odpowiedzi, a nast\u0119pnie kliknij \u201eOblicz wynik\u201d.';\n    document.getElementById('rx-egpa-result-note').innerHTML = 'Regu\u0142a: po spe\u0142nieniu warunku wst\u0119pnego zsumuj punkty. Wynik \u22656 pkt klasyfikuje EGPA wed\u0142ug ACR\/EULAR 2022.';\n  });\n})();\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Kalkulator klasyfikacyjny Eozynofilowa ziarniniakowato\u015b\u0107 z zapaleniem naczy\u0144 (EGPA) \u2014 ACR\/EULAR 2022 Kryteria stosuje si\u0119 po rozpoznaniu zapalenia naczy\u0144 ma\u0142ych lub \u015brednich naczy\u0144 oraz po wykluczeniu rozpozna\u0144 na\u015bladuj\u0105cych vasculitis. Nast\u0119pnie sumuje si\u0119 punkty; wynik \u22656 pkt klasyfikuje EGPA. 1. Warunek wst\u0119pny Czy rozpoznano zapalenie naczy\u0144 ma\u0142ych lub \u015brednich naczy\u0144 oraz wykluczono rozpoznania na\u015bladuj\u0105ce vasculitis? Nie Tak&#8230;<\/p>","protected":false},"author":1,"featured_media":0,"parent":980,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-371","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/comments?post=371"}],"version-history":[{"count":3,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/371\/revisions"}],"predecessor-version":[{"id":1156,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/371\/revisions\/1156"}],"up":[{"embeddable":true,"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/pages\/980"}],"wp:attachment":[{"href":"https:\/\/rheumanext.pl\/en\/wp-json\/wp\/v2\/media?parent=371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}